Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

NCT02691793 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02691793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02691793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Lead sponsor
Samsung Medical Center
Phase
Phase 4
Overall status
Completed
Start date
November 20, 2017
Completion date
November 19, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory solid tumors